Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C. Rochette is active.

Publication


Featured researches published by C. Rochette.


Biochimica et Biophysica Acta | 2000

The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs

Mark Abramovitz; Mohammed Adam; Yves Boie; Marie-Claude Carrière; Danielle Denis; Claude Godbout; Sonia Lamontagne; C. Rochette; Nicole Sawyer; Nathalie Tremblay; Michel Belley; Michel Gallant; Claude Dufresne; Yves Gareau; Rejean Ruel; Helene Juteau; Marc Labelle; Nathalie Ouimet; Kathleen M. Metters

Stable cell lines that individually express the eight known human prostanoid receptors (EP(1), EP(2), EP(3), EP(4), DP, FP, IP and TP) have been established using human embryonic kidney (HEK) 293(EBNA) cells. These recombinant cell lines have been employed in radioligand binding assays to determine the equilibrium inhibitor constants of known prostanoid receptor ligands at these eight receptors. This has allowed, for the first time, an assessment of the affinity and selectivity of several novel compounds at the individual human prostanoid receptors. This information should facilitate interpretation of pharmacological studies that employ these ligands as tools to study human tissues and cell lines and should, therefore, result in a greater understanding of prostanoid receptor biology.


Bioorganic & Medicinal Chemistry Letters | 1996

STRUCTURE ACTIVITY RELATIONSHIPS OF TETRAHYDROCANNABINOL ANALOGUES ON HUMAN CANNABINOID RECEPTORS

Yves Gareau; Claude Dufresne; Michel Gallant; C. Rochette; Nicole Sawyer; Deborah Slipetz; Nathalie Tremblay; Philip K. Weech; Kathleen M. Metters; Marc Labelle

A series of Δ8-tetrahydrocannabinol (THC) and biphenylic derivatives were prepared and their binding affinity for both human cannabinoid receptors hCB1 and hCB2 evaluated.


Bioorganic & Medicinal Chemistry Letters | 1996

New class of potent ligands for the human peripheral cannabinoid receptor

Michel Gallant; Claude Dufresne; Yves Gareau; Daniel Guay; Yves Leblanc; Petpiboon Prasit; C. Rochette; Nicole Sawyer; Deborah Slipetz; Nathalie Tremblay; Kathleen M. Metters; Marc Labelle

Abstract A new class of potent ligand for the human peripheral cannabinoid (hCB 2 ) receptor is described. Two indole analogs 13 and 17 exhibited nanomolar potencies (K i ) with good selectivity for the hCB 2 receptor over the human central cannabinoid (hCB 1 ) receptor.


Bioorganic & Medicinal Chemistry Letters | 1995

Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction

Marc Labelle; Michel Belley; Yves Gareau; Jacques-Yves Gauthier; Daniel Guay; Robert Gordon; S.G. Grossman; Thomas R. Jones; Yves Leblanc; M. McAuliffe; C. McFarlane; Paul Masson; Kathleen M. Metters; Nathalie Ouimet; D.H. Patrick; H. Piechuta; C. Rochette; Nicole Sawyer; Y.B. Xiang; C.B. Pickett; Anthony W. Ford-Hutchinson; Robert Zamboni; Robert N. Young

Abstract Structure-activity studies leading to the discovery of 1 (MK-0476) are described. The initial compound of this series, 2, was a potent leukotriene D4 (LTD4) antagonist, but was also a peroxisomal enzyme inducer in the mouse. Structure-activity relationships around the thioether chain were explored to remove this undesirable feature. It was found that alkyl substituents in the s position relative to the carboxylic acid reduce the potency as a peroxisomal enzyme inducer while preserving the LTD4 antagonistic properties. Dialkyl substitution essentially eliminates the enzyme induction. The optimal styryl quinoline 1 exhibited high in vitro potency and in vivo activity on oral dosing without significant liver enzyme induction in the mouse.


Bioorganic & Medicinal Chemistry Letters | 2002

Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor

Michel Gallant; Marie-Claude Carrière; Anne Chateauneuf; Danielle Denis; Yves Gareau; Claude Godbout; Gillian Greig; Helene Juteau; Nicolas Lachance; Patrick Lacombe; Sonia Lamontagne; Kathleen M. Metters; C. Rochette; Rejean Ruel; Deborah Slipetz; Nicole Sawyer; Nathalie Tremblay; Marc Labelle

Potent and selective ligands for the human EP3 prostanoid receptor are described. Biaryl compounds bearing a tethered ortho substituted acidic moiety were identified as potent EP3 antagonists based on the SAR described herein. The binding affinity of key compounds on all eight human prostanoid receptors is reported.


Bioorganic & Medicinal Chemistry Letters | 1999

New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor

Rejean Ruel; Patrick Lacombe; Mark Abramovitz; Claude Godbout; Sonia Lamontagne; C. Rochette; Nicole Sawyer; Rino Stocco; Nathalie Tremblay; Kathleen M. Metters; Marc Labelle

A new class of potent and selective ligands for the human EP1 prostanoid receptor is described. SAR studies reported herein allowed the identification of several potent dibenzazocinones bearing an acylsulfonamide side chain. The binding affinity of these compounds on all eight human prostanoid receptors is reported.


Bioorganic & Medicinal Chemistry Letters | 1995

Evolution of a series of non-quinoline leukotriene D4 receptor antagonist; synthesis and sar of benzothiazoles and thiazoles substituted benzyl alcohols as potent LTD4 antagonists

Cheuk K. Lau; Claude Dufresne; Yves Gareau; Robert Zamboni; Marc Labelle; Robert N. Young; Kathleen M. Metters; C. Rochette; Nicole Sawyer; Deborah Slipetz; L. Charette; Thomas R. Jones; M. McAuliffe; C. McFarlane; Anthony W. Ford-Hutchinson

Abstract Replacement of the quinoline pharmacophore of verlukast by alkylthiazoles and benzothiazoles has lead to the discovery of a new series of potent and orally active LTD4 receptor antagonists. The synthesis and structure activity relationships of this series of compounds are described.


Biochimica et Biophysica Acta | 1993

Identification and target-size analysis of the leukotriene D4 receptor in the human THP-1 cell line.

C. Rochette; Donald W. Nicholson; Kathleen M. Metters

The human acute monocytic leukemia cell line THP-1 has been identified, by radioligand binding, as expressing the leukotriene D4 receptor at a high level (4000 binding sites per cell), without the need for further cell differentiation. [3H]Leukotriene D4-specific binding to THP-1 cell membranes was of high affinity (KD = 0.47 nM) and saturable, enhanced by divalent cations but inhibited by both monovalent cations and non-hydrolyzable GTP analogs. The cysteinyl leukotrienes competed for [3H]leukotriene D4-specific binding with the following rank order of potency: leukotriene D4 >> leukotriene E4 > leukotriene C4. In addition, leukotriene D4-receptor antagonists from two structural classes, the quinolines MK-571 and L-697,008, and the indole ICI 204,219, displayed nanomolar potency in [3H]leukotriene D4 competition assays. These data show that [3H]leukotriene D4-specific binding to THP-1 cell membranes fulfils the criteria for binding to a leukotriene D4 receptor regulated through interaction with a G protein. Several novel features of the THP-1 leukotriene D4 receptor were investigated. Culture of THP-1 cells in the presence of tunicamycin, an inhibitor of N-glycosylation, resulted in a 6-fold decrease in the number of detectable [3H]leukotriene D4-specific binding sites. Target-size analysis by radiation inactivation estimated a molecular mass of 65 kDa for the [3H]leukotriene D4 specific binding site(s) present in THP-1 cell membranes. Together, these results suggest that the human THP-1 cell leukotriene D4 receptor is a glycosylated protein with a molecular mass of approx. 65 kDa within the membrane environment.


Bioorganic & Medicinal Chemistry Letters | 1998

A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair

Daniel Guay; Jacques-Yves Gauthier; Claude Dufresne; Thomas R. Jones; M. McAuliffe; C. McFarlane; Kathleen M. Metters; Petpiboon Prasit; C. Rochette; Patrick Roy; Nicole Sawyer; Robert Zamboni

The structure-activity relationship of a series of styrylpyridine analogs of MK-0476 (montelukast, Singulair) is described. This work has led to the identification of a number of potent and orally active cysLT1 receptor (LTD4 receptor) antagonists including 2ab (L-733,321) as an optimized candidate.


Bioorganic & Medicinal Chemistry Letters | 1994

The discovery of L-699,392, a novel potent and orally active leukotriene D4 receptor antagonist

Marc Labelle; Michel Belley; E. Champion; Robert Gordon; K. Hoogsteen; Thomas R. Jones; Yves Leblanc; A. Lord; M. McAuliffe; C. McFarlane; Paul Masson; Kathleen M. Metters; Deborah A. Nicoll-Griffith; Nathalie Ouimet; H. Piechuta; C. Rochette; Nicole Sawyer; Y.B. Xiang; James A. Yergey; Anthony W. Ford-Hutchinson; C.B. Pickett; Robert Zamboni; Robert N. Young

The styryl quinoline thioether 5 (L-699,392) is a potent and orally active leukotriene D4 antagonist. The structure-activity studies leading to its discovery are described.

Researchain Logo
Decentralizing Knowledge